Valneva (NASDAQ:VALN) Trading 7.1% Higher – What’s Next?

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) traded up 7.1% during mid-day trading on Wednesday . The company traded as high as $6.98 and last traded at $7.0340. 32,776 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 67,036 shares. The stock had previously closed at $6.57.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Valneva in a research report on Thursday, June 18th. TD Cowen began coverage on shares of Valneva in a research note on Tuesday, August 11th. They issued a “buy” rating and a $12.00 price target for the company. Finally, Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Two equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Valneva has an average rating of “Hold” and an average target price of $9.30.

Valneva Price Performance

The stock’s 50-day moving average is $5.57 and its 200 day moving average is $6.67. The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.69 and a current ratio of 2.16. The stock has a market capitalization of $662.33 million, a PE ratio of -3.30 and a beta of 1.67.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The company had revenue of $39.37 million during the quarter, compared to analysts’ expectations of $44.17 million. As a group, equities analysts expect that Valneva SE Sponsored ADR will post -1.27 earnings per share for the current year.

Institutional Trading of Valneva

Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new position in Valneva during the third quarter worth approximately $124,000. XTX Topco Ltd purchased a new stake in Valneva in the fourth quarter valued at approximately $94,000. Finally, Marex Group plc acquired a new stake in shares of Valneva in the second quarter valued at approximately $64,000. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.